Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Mycophenolate Mofetil

Review the clinical trials studying mycophenolate mofetil on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-46 of 46

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
Status: Active
Location: Yale University, New Haven, Connecticut
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Status: Active
Location: Yale University, New Haven, Connecticut
211^At-BC8-B10 before Donor Stem Cell Transplant in Treating Patients with High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Bendamustine with or without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
211At-BC8-B10 followed by Donor Stem Cell Transplant in Treating Patients with Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Daratumumab and Hyaluronidase-fihj before Standard Desensitization to Lower Donor-Specific Antibodies in Patients Undergoing Donor Bone Marrow or Peripheral Blood Stem Cell Transplantation
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Ruxolitinib with or without Abatacept for the Prevention of Graft Versus Host Disease and Cytokine Release Syndrome after T-cell Haploidentical Stem Cell Transplant in Patients with Hematologic Malignancies
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Infusion of Conventional and Regulatory T-Cells for the Treatment of Patients with Hematologic Malignancies Undergoing Reduced Intensity Donor Stem Cell Transplant
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer
Status: Enrolling by Invitation
Location: 2 locations
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients who Undergo a Hematopoietic Stem Cell Transplant
Status: Temporarily Closed to Accrual
Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients with Relapsed Hematologic Cancers Undergoing a Second or above Donor Stem Cell Transplant
Status: Temporarily Closed to Accrual
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Venetoclax, Busulfan, Fludarabine, Azacitidine, Decitabine, and Cedazuridine in Treating Patients with High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndromes Undergoing Donor Stem Cell Transplantation
Status: Temporarily Closed to Accrual
Location: 2 locations
Standard versus Low Dose Cyclophosphamide for Prevention of GVHD and Improvement in Quality of Life after Donor Stem Cell Transplant among Older Adults with Hematological Cancers
Status: Active
Location: University of Nebraska Medical Center, Omaha, Nebraska
Belumosudil for the Prevention of Graft-versus-Host Disease after Donor Hematopoietic Cell Transplant
Status: Active
Location: 7 locations
Post-Transplant Cyclophosphamide for the Prevention of Graft Versus Host Disease in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning for Hematological Diseases
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Abatacept in Combination with Mycophenolate Mofetil and Tacrolimus for the Prevention of Graft-versus-Host Disease after Omidubicel Hematopoietic Cell Transplant
Status: Active
Location: Duke University Medical Center, Durham, North Carolina